Questions and Answers on Adstiladrin | Gene Therapy for BCG Unresponsive NMIBC
In the second part of the presentation, Dr. Colin Dinney, principal investigator on the clinical trials that led to this approval of Adstiladrin, answers the most commonly asked questions about this novel therapy.
▶︎
Introduction to Adstiladrin | Gene Therapy for BCG Unresponsive NMIBC
▶︎
UROWebinar: NMIBC – BCG Unresponsive management in 2025 and new developments
▶︎
LIVE: Conan O’Brien speaks at Harvard graduation ceremony (full)
▶︎
Antineoplastic Agents | Clinical Medicine
▶︎
Let's Talk Pets And Emergencies in NZ
▶︎
Management of Non-Muscle Invasive Bladder Cancer
▶︎
Conan O’Brien Delivers the Commencement Address | Harvard Commencement 2026
▶︎
Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene in BCG-Unresponsive NMIBC
▶︎
Bladder Cancer Research & Therapies in the Pipeline: What’s Coming Next
▶︎
Personalizing Bladder Cancer Care in the Modern Therapeutic Era
▶︎
How to Translate New Bladder Cancer Therapies Into Practice
▶︎
Think Fast, Talk Smart: Communication Techniques
▶︎
Webinar: Exploring Rare Types of Bladder Cancer Part 1 of 4.
▶︎
Coaching Product Strategy
▶︎
Use These 5 Food Hacks To Heal The Body & STARVE CANCER I Dr. William Li
▶︎
He Chose Joy After a Stage-4 Cancer Diagnosis - Roland Wang’s Story of Faith & Rebuild
▶︎
Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: 5-Year Follow-Up
▶︎
Working Smarter to Prevent Bladder Cancer: How Jobs and the Environment Affect Risk. Part 2 of 4.
▶︎
Webinar: Exploring Rare Types of Bladder Cancer Part 4 of 4.
▶︎